Recipharm Lifesciences India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-07-2024
- Paid Up Capital ₹ 0.10 M
as on 17-07-2024
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -19.89%
(FY 2023)
- Profit -15.60%
(FY 2023)
- Ebitda 43.48%
(FY 2023)
- Net Worth 0.01%
(FY 2023)
- Total Assets 0.01%
(FY 2023)
About Recipharm Lifesciences India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Suresh Ganachari, Emmanuel Grand, and Rohit Sidhwani serve as directors at the Company.
- CIN/LLPIN
U51909HP2017PTC006464
- Company No.
006464
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Feb 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Poanta Sahib, Himachal Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Recipharm Lifesciences India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suresh Ganachari  | Director | 28-Nov-2022 | Current |
| Emmanuel Grand | Director | 06-Jan-2023 | Current |
| Rohit Sidhwani | Director | 22-Feb-2023 | Current |
Financial Performance and Corporate Structure Insights of Recipharm Lifesciences India.
Recipharm Lifesciences India Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 19.89% decrease. The company also saw a substantial fall in profitability, with a 15.6% decrease in profit. The company's net worth moved up by a moderate rise of 0.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Recipharm Lifesciences India?
In 2022, Recipharm Lifesciences India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Recipharm Pharmaservices Private Limited
Active 8 years 10 monthsSuresh Ganachari is a mutual person
Recipharm Holding India Private Limited
Active 8 years 7 monthsSuresh Ganachari, Emmanuel Grand and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Recipharm Lifesciences India?
Unlock and access historical data on people associated with Recipharm Lifesciences India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Recipharm Lifesciences India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Recipharm Lifesciences India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
